[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=980cf58dea7d97baade78c1fe71a83a4e5e97eb6e8c0512f624b2896be6ca863",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740069540,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 132838600,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=980cf58dea7d97baade78c1fe71a83a4e5e97eb6e8c0512f624b2896be6ca863"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer",
    "summary": "PRINCETON, N.J. - Bristol Myers Squibb today announced the final analysis of overall survival from the Phase 3 CheckMate -816 study, which evaluated Opdivo in combination with platinum-doublet...",
    "url": "https://finnhub.io/api/news?id=916e993b129d4f507ae3d87ed3f79149c93266706d5c9d7ca5316e240f673b7f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740045439,
      "headline": "Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer",
      "id": 132801661,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "PRINCETON, N.J. - Bristol Myers Squibb today announced the final analysis of overall survival from the Phase 3 CheckMate -816 study, which evaluated Opdivo in combination with platinum-doublet...",
      "url": "https://finnhub.io/api/news?id=916e993b129d4f507ae3d87ed3f79149c93266706d5c9d7ca5316e240f673b7f"
    }
  }
]